Leuven, BELGIUM, Boston, MA, US - March 25,2022 - 09.00 PM CET -Oxurion NV(Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2021.

The annual report for the year ended 2021 is available in the "Investors" section of the Company's website and can also be downloaded as a PDF.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Oxurion NV published this content on 25 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2022 20:10:41 UTC.